Skip to main content
Explore URMC

menu

Blood Cancer: Denosumab for Smoldering Multiple Myeloma

Research Question:
Is denosumab, delivered as an injection under the skin, safe and well-tolerated in people with smoldering multiple myeloma? And can denosumab reduce the risk of getting multiple myeloma?

Basic Study Information

Purpose:
This is a trial of denosumab 120mg subcutaneous (under the skin) for patients with smoldering multiple myeloma (SMM). SMM is a plasma cell disorder has a high risk of progressing to multiple myeloma (MM). Participants will be recruited from the James P. Wilmot Cancer Center, University of Rochester in Rochester, New York. Patients seen in the inpatient or outpatient setting with histologically confirmed SMM will be evaluated for this study. 20 patients will be treated with a dose of denosumab every 4 weeks over the course of a year. Patients will be followed after completion of the study for an additional 2 years. All patients will take daily vitamin D and calcium supplements.

Location: University of Rochester Medical Center
Study Reference #: UMMY18121

Lead Researcher (Principal Investigator)

Lead Researcher: Brea Lipe

Study Contact Information

Study Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Email: Kaitlyn_Burrows@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search